Visceral leishmaniasis and HIV coinfection: current perspectives

Lindoso, José Ângelo Lauletta; Moreira, Carlos Henrique Valente; Cunha, Mirella Alves; Queiróz, Igor Thiago.
HIV AIDS (Auckl) ; 10: 193-201, Oct. 2018. tab
Artículo en Inglés | SES-SP, SESSP-IIERPROD, SES-SP | ID: biblio-1021385

Documentos relacionados

  1. Splenectomy for Visceral Leishmaniasis Out of an Endemic Region: A Case Report and Literature Review.
  2. In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes.
  3. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
  4. SHIP1 inhibition via 3-alpha-amino-cholestane enhances protection against Leishmania infection.
  5. Exploring Novel Drug Combinations: The Therapeutic Potential of Selanyl Derivatives for Leishmania Treatment.
  6. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
  7. Stigmasterol as a potential biomarker for amphotericin B resistance in Leishmania donovani.
  8. Therapeutic potential of rWnt5A in curbing <i>Leishmania donovani</i> infection.
  9. Effects of terpenes in the treatment of visceral leishmaniasis: A systematic review of preclinical evidence.
  10. Visceral leishmaniasis in an infant gorilla (Gorilla gorilla gorilla): Clinical signs, diagnosis, and successful treatment with single-dose liposomal amphotericin B.